TNFRSF8 and cancer: It is noteworthy that it has been described that CD30+ EVs bind to CD30L on bystander cells and present additional membrane-associated CD30 sites for the binding and toxic activity of Brentuximab-Vedotin, suggesting the dual targeting of cancer and bystander cells [79].